Fig. 1

HK2 is overexpressed in EC and predicts a worse prognosis. a Genomic profiling of HK2 across human cancers was determined using cBioPortal. b Analysis of HK2 expression in different cancer tissues compared with corresponding normal tissues in datasets available at Oncomine. Red: upregulation; blue: downregulation. The numbers in the boxes represent the number of studies that met our thresholds. c DNA copy number profile of HK2 in endometrial cancer (EC) tissues and normal tissues using the TCGA data from Oncomine. EEC: endometrial endometrioid carcinoma. d The protein expression of HK2 in EC and normal tissues was analyzed using UALCAN. e The protein expression of HK2 in normal tissues and subgroups of patients with EC stratified based on tumor grade (UALCAN). f The microarray dataset (GSE17025) was analyzed for HK2 expression in stage I EC samples and normal endometrium samples. g The protein expression of HK2 was examined in EC tissue and adjacent normal tissues. Images were downloaded from Human Protein Atlas. h HK2 expression was measured in a normal endometrial cell line (EM) and human EC cell lines using quantitative real-time PCR and western blotting analysis. i Kaplan-Meier overall survival analysis was used to assess EC patients with high or low HK2 expression from KM Plotter. j The patients from the TCGA EC dataset in SurvExpress were divided into low- and high-risk groups, and survival differences between the two groups were compared using Kaplan-Meier analysis (left panel). The expression level of HK2 in low- and high-risk groups was examined (right panel). *P < 0.05